© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Ishmeal and Gloria Boles have put their lives back together after his devastating lung cancer diagnosis.
Lurbinectedin shrank tumors in a third of people with this less common type of lung cancer.
The use of the algorithm helped increase these kids’ progression-free survival.
Ramucirumab slowed disease progression more than a placebo when added to erlotinib.
Psychologist Seth Axelrod, PhD, has metastatic bone cancer—and a unique set of therapeutic skills that help him live with it.
Study showed 74% overall response rate for people who used brigatinib as their first ALK inhibitor.
New targeted therapy delayed disease progression compared with a placebo.
Selpercatinib, the first drug in its class, shrank tumors in over two thirds of previously treated patients.
The PARP inhibitor delayed disease progression by 20 months compared with a placebo.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
